2005
The relationship between non‐injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use
Kapadia F, Cook J, Cohen M, Sohler N, Kovacs A, Greenblatt R, Choudhary I, Vlahov D. The relationship between non‐injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 2005, 100: 990-1002. PMID: 15955015, PMCID: PMC3128378, DOI: 10.1111/j.1360-0443.2005.01098.x.Peer-Reviewed Original ResearchConceptsNon-injection drug useWomen's Interagency HIV StudyHIV progressionMultivariate analysisActive antiretroviral therapy (HAART) eraActive antiretroviral therapy (HAART) useMultivariate Cox proportional hazardsAntiretroviral therapy eraAntiretroviral therapy useFormer usersHIV-seropositive womenProspective cohort studyCells/Cox proportional hazardsDrug use behaviorsUse of stimulantsCause deathHAART initiationHAART utilizationTherapy eraCause mortalityHAART useSeropositive womenAIDS eventsCohort study
2003
Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S, Coutinho R, Eugen-Olsen J, Gallart T, Katzenstein T, Kostrikis L, Kuipers H, Louie L, Mallal S, Margolick J, Martinez O, Meyer L, Michael N, Operskalski E, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Stewart G, Theodorou I, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J, O'Brien T. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Annals Of Internal Medicine 2001, 135: 782-95. PMID: 11694103, DOI: 10.7326/0003-4819-135-9-200111060-00008.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCCR2-64I alleleHIV-1 RNA levelsHIV-1 disease progressionDevelopment of AIDSIndividual patient dataCCR5-Delta32Decreased riskDisease progressionProtective effectLower HIV-1 RNA levelsRNA levelsProspective cohort studyCase-control studyClear protective effectStrong protective effectChemokine receptor genesRandom-effects modelCCR2-64ICohort studyStudy entryCertain chemokinesAIDSInfectionProgressionEffect of a Single Amino Acid Change in MHC Class I Molecules on the Rate of Progression to AIDS
Gao X, Nelson G, Karacki P, Martin M, Phair J, Kaslow R, Goedert J, Buchbinder S, Hoots K, Vlahov D, O'Brien S, Carrington M. Effect of a Single Amino Acid Change in MHC Class I Molecules on the Rate of Progression to AIDS. New England Journal Of Medicine 2001, 344: 1668-1675. PMID: 11386265, DOI: 10.1056/nejm200105313442203.Peer-Reviewed Original ResearchConceptsRate of progressionHIV-1 infectionClass IHuman immunodeficiency virus type 1 (HIV-1) infectionDifferent peptide-binding specificitiesVirus type 1 infectionRisk of progressionT lymphocyte responsesInfluence of HLAType 1 infectionHIV-1 epitopesSubtypes of HLAHLA class IPeptide-binding specificityMHC class I moleculesAmino acid changesComplex class ISingle amino acid changeClass I moleculesReactive HLAImmunodeficiency syndromeRelated HLAPx groupCommon HLAHIV-1Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study
Ickovics J, Hamburger M, Vlahov D, Schoenbaum E, Schuman P, Boland R, Moore J, Group F. Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study. JAMA 2001, 285: 1466-1474. PMID: 11255423, DOI: 10.1001/jama.285.11.1466.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusChronic depressive symptomsCD4 cell countHIV-seropositive womenTreatment of depressionDepressive symptomsCell countDisease progressionBaseline CD4 cell countCD4 cell count declineHIV Epidemiologic Research StudyCell count declineCD4 lymphocyte countBaseline viral loadEpidemiologic Studies Depression ScaleHIV disease progressionHIV Epidemiology Research StudyLongitudinal cohort studyEpidemiologic research studiesImpact of depressionAcademic medical centerSelf-reported CenterCohort studyLymphocyte countCount decline
1999
Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, Farzadegan H. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. European Journal Of Epidemiology 1999, 15: 99-108. PMID: 10204638, DOI: 10.1023/a:1007556327269.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionFemaleFollow-Up StudiesHIV InfectionsHIV-1Homosexuality, MaleHumansImmunocompromised HostLeukocytes, MononuclearMalePredictive Value of TestsProportional Hazards ModelsRisk FactorsSubstance Abuse, IntravenousSurvival AnalysisSurvival RateViral LoadViremiaConceptsHIV-1 viral loadViral loadHomosexual menRisk groupsHIV-1Relative hazardDrug usersPeripheral blood mononuclear cellsMicroculture techniqueBlood mononuclear cellsInjection drug usersHIV-1 progressionInitial CD4Clinical progressionMononuclear cellsNegative culturesPredictive valueSurvival analysisBacterial infectionsTotal participantsAIDSProgressionInfectious unitsCells/Death
1998
Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5
Martin M, Dean M, Smith M, Winkler C, Gerrard B, Michael N, Lee B, Doms R, Margolick J, Buchbinder S, Goedert J, O'Brien T, Hilgartner M, Vlahov D, O'Brien S, Carrington M. Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5. Science 1998, 282: 1907-1911. PMID: 9836644, DOI: 10.1126/science.282.5395.1907.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAllelesChemokine CXCL12Chemokines, CXCCohort StudiesDisease ProgressionGenes, DominantGenes, RecessiveGenetic Predisposition to DiseaseGenotypeHaplotypesHeterozygoteHIV InfectionsHIV-1HomozygoteHumansPromoter Regions, GeneticProportional Hazards ModelsReceptors, CCR2Receptors, CCR5Receptors, ChemokineReceptors, CytokineRisk FactorsSurvival RateConceptsAIDS progressionCell-surface chemokine receptor moleculeCCR5 regulatory regionsChemokine receptor moleculesPercent of patientsAIDS disease progressionHIV-1 infectionCohort of peopleMacrophage-tropic strainsAIDS restriction genesDistinct regulatory influencesCCR2-64IPrincipal coreceptorImmunodeficiency syndromeCCR5-Delta32Genetic epidemiologic analysisDisease progressionHuman immunodeficiencySDF1-3'APromoter genotypeCCR5 geneInfected individualsEpidemiologic analysisHost factorsProgressionSex differences in HIV-1 viral load and progression to AIDS
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, Quinn T, Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1998, 352: 1510-1514. PMID: 9820299, DOI: 10.1016/s0140-6736(98)02372-1.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell countProportional hazards modelBranched-chain DNAViral loadQuantitative microcultureReverse transcriptase-PCRPlasma HIV-1 RNA measurementsCell countHIV-1 RNA measurementsUnivariate proportional hazard modelHIV-1 viral loadSame viral loadViral load associationsVisit 3 yearsHIV-1 loadViral load measurementsAntiretroviral therapyAntiretroviral treatmentBaseline visitCommunity clinicsObservational studyHIV-1Current recommendationsHigh riskPrognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett J, Margolick J, Lyles C, Nelson K, Smith D, Holmberg S, Farzadegan H. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 1998, 279: 35-40. PMID: 9424041, DOI: 10.1001/jama.279.1.35.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBiomarkersBlack or African AmericanCD4 Lymphocyte CountDisease ProgressionFemaleHIV-1HumansMalePrognosisProportional Hazards ModelsProspective StudiesRegression AnalysisRNA, ViralSubstance Abuse, IntravenousSurvival AnalysisViral LoadConceptsInfectious disease deathsInjection drug usersPlasma viral loadViral loadDisease deathsCell countDrug usersPrognostic indicatorHuman immunodeficiency virus type 1 (HIV-1) viral loadAfrican American injection drug usersPlasma HIV-1 RNAHIV-1 viral loadInfectious diseasesClinical AIDS diagnosisLevels of CD4Kaplan-Meier analysisHIV-1 RNAPrognosis of personsPowerful prognostic informationProportional hazards modelCases of AIDSGood predictive valueCell count measurementsMedian followCohort study
1997
Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression
Smith M, Dean M, Carrington M, Winkler C, Huttley G, Lomb D, Goedert J, O'Brien T, Jacobson L, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner M, Study H, San Francisco City Cohort ALIVE Study M, O'Brien S. Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression. Science 1997, 277: 959-965. PMID: 9252328, DOI: 10.1126/science.277.5328.959.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBlack PeopleCohort StudiesDisease ProgressionGenotypeHaplotypesHeterozygoteHIV InfectionsHIV-1HumansMutationPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single-Stranded ConformationalProportional Hazards ModelsReceptors, CCR2Receptors, CCR5Receptors, ChemokineReceptors, CytokineReceptors, HIVSurvival AnalysisWhite PeopleConceptsHIV-1 infectionCCR2-64IDisease progressionHIV-1 disease progressionHIV-1-infected individualsLong-term survivorsCCR2-64I alleleReceptor geneChemokine receptor genesAIDS 2CCR2 chemokineSyndrome cohortAIDS patientsCCR5-Delta32Human immunodeficiencyChemokine receptorsCCR5 variantsCCR2CCR5InfectionIndependent effectsAfrican AmericansMutant genotypesProgressionGenetic association analysis
1996
Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion
Pezzotti P, Phillips A, Dorrucci M, Lepri A, Galai N, Vlahov D, Rezza G. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. The BMJ 1996, 313: 583. PMID: 8806246, PMCID: PMC2352019, DOI: 10.1136/bmj.313.7057.583.Peer-Reviewed Original ResearchConceptsDate of seroconversionCategories of exposureExposure categoriesOlder subjectsInjected drugsMore rapid progressionHeterosexual sexLongitudinal studyHomosexual sexHIV treatmentAIDS pathogenesisUnivariate analysisRapid progressionAge effectsYoung subjectsHomosexual menHIVRate of developmentEvidence of differencesDisease controlAIDSSeroconversionSexAgeDefinitions of Center
1994
Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users
Aylward R, Vlahov D, Muñoz A, Rapiti E. Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users. AIDS 1994, 8: 1129-1134. PMID: 7986411, DOI: 10.1097/00002030-199408000-00015.Peer-Reviewed Original ResearchConceptsIntravenous drug usersClinical stage 1Proportional hazards modelStaging systemProduct limit estimatesWorld Health OrganizationALIVE studyHIV diseaseHazards modelPopulation of IVDUWorld Health Organization (WHO) staging systemDrug usersCox proportional hazards modelStage 1WHO staging systemTime of progressionStage 2Index visitHIV seropositivityHIV-seropositivePrognostic utilityClinical stageClinical criteriaOriginal cohortClinical signs